- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02298699
Biomarker for Sly Disease (MPS VII) (BioSly) (BioSly)
Biomarker for Sly Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL
Study Overview
Status
Detailed Description
Mucopolysaccharidosis type VII (also known as Sly syndrome or Sly disease) is an inherited disease caused by a lack of the enzyme beta-glucuronidase. This enzyme is needed to break down substances in the body called glycosaminoglycans (GAGs). If the enzyme is not present, GAGs cannot be broken down and they build up in the cells and damage them. This causes a wide range of problems such as short stature, skeletal abnormalities, joint stiffness, enlarged spleen and liver, lung infections, heart problems and hernias. Patients usually die within the first year of life, although some survive into their teenage years.
Mucopolysaccharidosis type VII is a life-threatening disease with many patients dying in early childhood. It also debilitating due to the physical and skeletal abnormalities that occur.
Sly syndrome is characterized by coarse facial features, hepatosplenomegaly, protruding sternum and dystosis multiplex. Dystosis multiplex refers to a constellation of skeletal abnormalities and is characterized by an enlarged skull, thickened calvarium, premature closure of lamboid and sagittal sutures, shallow orbits, enlarged J-shaped sella and abnormal spacing of the teeth with dentigerous cysts. There is anterior hypoplasia of the lumbar vertebrae, the long bone diaphyses are enlarged and an irregular appearance of the metaphyses. The epiphyseal centers not well developed, the pelvis is poorly formed with small femoral heads and coxa valga. The clavicles are short, thick and irregular and the ribs are oar shaped. Phalanges are shortened and trapezoidal in shape.
At the time of designation, mucopolysaccharidosis type VII affected approximately 0.001 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 50 people, and is below the ceiling for orphan designation, which is 5 people in 10,000.
New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood (plasma) of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.
Therefore it is the goal of the study to identify and validate a new biochemical marker from the plasma of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.
Study Type
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 89075
- Children's Hospital, Faculty of Medicine, Ain Shams University
-
-
-
-
-
Rostock, Germany, 18055
- Centogene AG
-
-
-
-
-
Mumbai, India, 400705
- Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)
-
-
Kerala
-
Cochin, Kerala, India, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
-
-
-
Colombo 8, Sri Lanka, 00800c
- Lady Ridgeway Hospital for Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
INCLUSION CRITERIA:
- Informed consent will be obtained from the parents before any study related procedures
- Patients of both genders older than 2 months
- The patient has a diagnosis of Sly disease or a high-grade suspicion for Sly disease
- High-grade suspicion present, if one or more inclusion criteria are valid:
Positive family anamnesis for Sly disease
Developmental delay and/or progressive mental deterioration
Skeletal abnormalities
Hepatomegaly
Splenomegaly
EXCLUSION CRITERIA:
- No Informed consent from the parents before any study related procedures.
- Patients of both genders younger than 2 months
- No diagnosis of Sly disease or no valid criteria for profound suspicion of Sly disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Observation
Patients with Sly disease or high-grade suspicion for Sly disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
Time Frame: 24 months
|
New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Testing for clinical robustness, specificity and long-term stability of the biomarker
Time Frame: 36 months
|
the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.
|
36 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Pathological Conditions, Anatomical
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Mucopolysaccharidoses
- Hypertrophy
- Splenomegaly
- Hepatomegaly
- Mucopolysaccharidosis VII
Other Study ID Numbers
- BSLY 06-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Developmental Delay
-
Tokat Gaziosmanpasa UniversityRecruiting
-
Florida Gulf Coast UniversityRecruitingDevelopmental DelayUnited States
-
Taipei Medical UniversityNot yet recruiting
-
Hacettepe UniversityCompleted
-
Salus UniversityActive, not recruitingDevelopmental DelayUnited States
-
University of Colorado, DenverChildren's Hospital Colorado; Bright by 3; Daniels Fund; Piton Foundation; Gantz...Terminated
-
Amar Seva SangamUniversity of Toronto; Grand Challenges CanadaCompleted
-
Children's Hospital Medical Center, CincinnatiOffice of Head StartCompleted
-
Texas Woman's UniversityCompleted
-
Taipei Medical UniversityShin Kong Wu Ho-Su Memorial HospitalUnknown